DENVER, January 29, 2026 — Leads & Copy — SeaStar Medical Holding Corporation (Nasdaq: ICU) announced that CEO Eric Schlorff will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 5th at 11:30 am Eastern Time. The company is a commercial-stage healthcare company focused on treatments for critically ill patients facing organ failure.
Interested investors and guests can register for the live investor presentations at the Virtual Equity Conference Registration.
A replay of the presentation will be available on February 9th after 11:30 am Eastern Time on the Company’s website. The replay will be available for up to 30 days following its posting.
SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure. The QUELIMMUNE (SCD-PED) therapy is its first commercial product based on Selective Cytopheretic Device (SCD) technology.
The QUELIMMUNE (SCD-PED) therapy, approved in 2024 by the FDA, is the only FDA approved product for life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. The company’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA.
SeaStar is conducting the NEUTRALIZE-AKI pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), impacting over 200,000 adults in the U.S. annually.
For more information visit SeaStar Medical on LinkedIn or X.
Source: SeaStar Medical
